High-resolution melting analysis for mutation screening of RGSL1, RGS16, and RGS8 in breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 2, 2011, Pages 397-407

  Wiechec, Emilia ^a,b   Wiuf, Carsten ^a   Overgaard, Jens ^b   Hansen, Lise Lotte ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RGS PROTEIN; RGS16 PROTEIN; RGS8 PROTEIN; RGSL1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CASE CONTROL STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HIGH RESOLUTION MELTING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DENMARK; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEINS; RGS PROTEINS; TRANSITION TEMPERATURE;

EID: 79951588064     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0514     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-51. (Pubitemid 38406580)
3. Spiegelberg BD, Hamm HE. Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription. Curr Opin Genet Dev 2007;17:40-4. (Pubitemid 46109292)
4. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90. (Pubitemid 46763021)
5. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92. (Pubitemid 43292562)
6. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
8. Vivanco I, Sawyers L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
10. Wiechec E, Hansen LL. The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol 2009;625:122-30.
11. Nebert DW. Pharmacogenetics and human cancer. IARC Sci Publ 1982;365-80.
12. Sjoqvist F. The past, present and future of clinical pharmacology. Eur J Clin Pharmacol 1999;55:553-7. (Pubitemid 29489200)
13. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-4. (Pubitemid 26391460)
14. Rökman A, Ikonen T, Seppälä EH, Nupponen N, Autio V, Mononen N, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70:1299-304. (Pubitemid 34450579)
15. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
16. Lopez-Otin C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998;19:365-96. (Pubitemid 29116015)
17. Sevinç A, Yannoukakos D, Konstantopoulou I, Manguoglu E, Lüleci G, Colak T, et al. Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer. Anticancer Res 2004;24:2547-9. (Pubitemid 39166345)
18. Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, Nordsmark M, et al. Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS One 2008;3:e2492.
19. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54:527-59.
20. Koelle MR. A new family of G-protein regulators - the RGS proteins. Curr Opin Cell Biol 1997;9:143-7. (Pubitemid 27135979)
21. Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000;69:795-827.
22. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94. (Pubitemid 46164746)
23. Hurst JH, Hooks SB. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol 2009;78:1289-97.
24. Devilee P, van Vliet M, Bardoel A, Kievits T, Kuipers-Dijkshoorn N, Pearson PL, et al. Frequent somatic imbalance of marker alleles for chromosome 1 in human primary breast carcinoma. Cancer Res 1991;51:1020-5.
25. Chen LC, Dollbaum C, Smith HS. Loss of heterozygosity on chromosome 1q in human breast cancer. Proc Natl Acad Sci U S A 1989;86:7204-7. (Pubitemid 19240894)
26. Bieche I, Champeme MH, Lidereau R. Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1995;1:123-7.
27. Wiechec E, Overgaard J, Hansen LL. A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer 2008;47:766-80.
28. Gundry CN, Vandersteen JG, Reed GH, Pryor RJ, Chen J, Wittwer CT. Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem 2003;49:396-406. (Pubitemid 36250200)
29. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007; 35:e41.
30. Herrmann MG, Durtschi JD, Bromley LK, Wittwer CT, Voelkerding KV. Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 2006;52:494-503.
31. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007;8:597-608. (Pubitemid 46939585)
32. Montgomery J, Wittwer CT, Palais R, Zhou L. Simultaneous mutation scanning and genotyping by high-resolution DNA melting analysis. Nat Protoc 2007;2:59-66. (Pubitemid 47040069)
33. Pati N, Schowinsky V, Kokanovic O, Magnuson V, Ghosh S. A comparison between SNaPshot, pyrosequencing, and biplex invader SNP genotyping methods: accuracy, cost, and throughput. J Biochem Biophys Methods 2004;60:1-12. (Pubitemid 38952847)
34. Makridakis NM, Reichardt JK. Multiplex automated primer extension analysis: simultaneous genotyping of several polymorphisms. Biotechniques 2001;31:1374-80. (Pubitemid 33131222)
35. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998;58:2166-9. (Pubitemid 28232903)
36. Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. Apmis 1998;106:371-7. (Pubitemid 28157213)
37. POLAND service. Available from:http://www.biophys.uni-duessel-dorf.de/ local/POLAND/poland.html.
38. BLAT Search Genome, UCSC Genome Bioinformatics. Available from: http://genome.ucsc.edu/cgi-bin/hgBlat?command=start.
39. Oligo Calc. Available from: http://www.basic.northwestern.edu/biotools/ oligocalc.html.
40. Russel Lenth's power and sample-size page. Available from: http://www.stat.uiowa.edu/~rlenth/Power/.
41. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-50. (Pubitemid 34987785)
42. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol Ther 2007;116:473-95. (Pubitemid 350116944)
43. Chowdari KV, Bamne M, Wood J, Talkowski ME, Mirnics K, Levitt P, et al. Linkage disequilibrium patterns and functional analysis of RGS4 polymorphisms in relation to schizophrenia. Schizophr Bull 2008;34:118-26. (Pubitemid 350262278)
44. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008;40:395-402. (Pubitemid 351450876)
45. Gu J, Wu X, Dong Q, Romeo MJ, Lin X, Gutkind JS, et al. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. Cancer 2006;106:2716-24.
46. Berman DM, Wang Y, Liu Z. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 2004;64:6820-6. (Pubitemid 39297947)
47. Liang G, Bansal G, Xie Z, Druey KM. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem 2009;284:21719-27.
48. Derrien A, Druey KM. RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation. J Biol Chem 2001;276:48532-8.
49. Buckbinder L, Velasco-Miguel S, Chen Y, Xu N, Talbott R, Gelbert L, et al. The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A 1997;94:7868-72. (Pubitemid 27343741)
50. Druey KM, Blumer KJ, Kang VH, Kehrl JH. Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family. Nature 1996;379:742-6. (Pubitemid 26061739)
51. Johnson GL. Signal transduction abnormalities in cancer mitogen-activated protein kinase regulation is altered in breast cancer. J Clin Invest 1997;99:1463-4. (Pubitemid 27163794)
52. Saitoh O, Masuho I, Itoh M, Abe H, Komori K, Odagiri M. Distribution of regulator of G protein signaling 8 (RGS8) protein in the cerebellum. Cerebellum 2003;2:154-60. (Pubitemid 38282198)